Polynovo Ltd (ASX: PNV) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Polynovo Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$1.35 billion
P/E Ratio
282.67
Dividend Yield
0.00%
Shares Outstanding
690.84 million
Earnings per share
0.008
Dividend per share
N/A
Year To Date Return
28.10%
Earnings Yield
0.35%
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Polynovo Ltd (ASX: PNV)
Latest News
Share Market News
ASX 200 Weekly Wrap: COVID wobbles ASX as shares retreat
Share Fallers
These were the worst performing ASX 200 shares last week
Healthcare Shares
Why did the Polynovo (ASX:PNV) share price drop 15% in May?
Share Gainers
These were the best performing ASX 200 shares in March
Share Market News
Brokers think these ASX 200 shares will outperform the market
Broker Notes
Top brokers name 3 ASX shares to buy next week
Share Fallers
Why Galilee Energy, Hansen, Polynovo, & TPG shares are tumbling lower
Share Market News
Brokers are bullish on these 4 ASX 200 shares
Share Gainers
The PolyNovo (ASX:PNV) share price jumps 5% with its latest news
Healthcare Shares
ASX medical shares report promising half-year results
Share Market News
What's happening with the PolyNovo (ASX:PNV) share price?
Share Market News
PolyNovo (ASX:PNV) share price advances 4% higher on market update
Frequently Asked Questions
-
The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was listed on the ASX on 26 November 1998 and is headquartered in Melbourne.
-
No, the company does not historically pay dividends.
PNV ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Polynovo Ltd
PolyNovo Ltd (ASX: PNV) develops and commercialises innovative medical devices using its patented NovoSorb technology.
NovoSorb is a family of biocompatible polymers that are used in the treatment of burns and surgical wounds. They biodegrade into by-products that can be absorbed and excreted by the body. For example, its NovoSorb BTM (Biodegradable Temporising Matrix) can be used to temporarily close a wound and aid the body in generating new tissue.
PolyNovo’s products are sold across Australia and New Zealand, the United States, the United Kingdom, and Europe.
PNV Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 20 Dec 2024 | $1.95 | $-0.06 | -2.99% | 1,600,830 | $2.00 | $2.02 | $1.94 |
| 19 Dec 2024 | $2.01 | $-0.11 | -5.19% | 2,538,423 | $2.05 | $2.07 | $1.98 |
| 18 Dec 2024 | $2.12 | $0.03 | 1.44% | 1,267,359 | $2.09 | $2.21 | $2.08 |
| 17 Dec 2024 | $2.09 | $0.02 | 0.97% | 758,417 | $2.08 | $2.10 | $2.06 |
| 16 Dec 2024 | $2.07 | $0.00 | 0.00% | 1,033,671 | $2.06 | $2.09 | $2.03 |
| 13 Dec 2024 | $2.07 | $-0.04 | -1.90% | 1,684,060 | $2.08 | $2.09 | $2.01 |
| 12 Dec 2024 | $2.11 | $-0.01 | -0.47% | 1,018,595 | $2.12 | $2.13 | $2.09 |
| 11 Dec 2024 | $2.12 | $-0.03 | -1.40% | 1,013,997 | $2.13 | $2.15 | $2.08 |
| 10 Dec 2024 | $2.15 | $-0.08 | -3.59% | 1,536,886 | $2.26 | $2.28 | $2.15 |
| 09 Dec 2024 | $2.23 | $0.01 | 0.45% | 707,727 | $2.21 | $2.27 | $2.21 |
| 06 Dec 2024 | $2.22 | $-0.04 | -1.77% | 678,528 | $2.25 | $2.27 | $2.21 |
| 05 Dec 2024 | $2.26 | $0.04 | 1.80% | 842,963 | $2.24 | $2.29 | $2.21 |
| 04 Dec 2024 | $2.22 | $-0.03 | -1.33% | 787,704 | $2.20 | $2.24 | $2.19 |
| 03 Dec 2024 | $2.25 | $0.06 | 2.74% | 707,985 | $2.23 | $2.27 | $2.22 |
| 02 Dec 2024 | $2.19 | $-0.01 | -0.45% | 679,307 | $2.22 | $2.22 | $2.17 |
| 29 Nov 2024 | $2.20 | $0.04 | 1.85% | 857,101 | $2.22 | $2.23 | $2.16 |
| 28 Nov 2024 | $2.16 | $0.02 | 0.93% | 1,207,910 | $2.17 | $2.23 | $2.15 |
| 27 Nov 2024 | $2.14 | $0.08 | 3.88% | 1,480,156 | $2.09 | $2.16 | $2.04 |
| 26 Nov 2024 | $2.06 | $0.02 | 0.98% | 1,628,790 | $2.04 | $2.09 | $2.03 |
| 25 Nov 2024 | $2.04 | $0.06 | 3.03% | 2,540,301 | $2.02 | $2.04 | $2.00 |
| 22 Nov 2024 | $1.98 | $-0.01 | -0.50% | 669,444 | $2.05 | $2.05 | $1.97 |
| 21 Nov 2024 | $1.99 | $-0.04 | -1.97% | 828,477 | $2.04 | $2.05 | $1.96 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 30 Sep 2024 | Andrew Lumsden | Sell | 50,000 | $130,915 |
On-market trade.
|
| 26 Sep 2024 | Leon Hoare | Sell | 100,000 | $260,839 |
On-market trade. As per announcement on 02-01-2024
|
| 13 Sep 2024 | Bruce Rathie | Sell | 750,000 | $1,886,900 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr David Williams | Non-Executive DirectorNon-Executive Chairman | Feb 2014 |
Mr Williams is a director and investment banker with a track record in business development, mergers and acquisitions, and capital raising. He has experience advising companies in the food, medical device, and pharmaceutical sectors. Mr Williams is currently Managing Director of corporate advisory firm Kidder Williams.
|
| Dr Robyn Elliott | Non-Executive Director | Oct 2019 |
Dr Elliott has a track record in product development, clinical trials, regulatory affairs, audits, quality management, project management and operational strategy. Her worldwide experience in new facility delivery, production scale up, strategy, regulatory affairs and audit will be invaluable to PolyNovo as the company scales its operations globally. Dr Elliott was Global Head, Strategic Portfolio Management at CSL Behring, a role that is responsible for governance oversight and business value delivery. Dr Elliott is a member of the Risk Committee.
|
| Mr Andrew Stuart Lumsden | Non-Executive Director | Jun 2021 |
Mr Lumsden has more than 20 years of experience locally and internationally. Mr Lumsden is currently Chief Executive Officer of Wellcom Worldwide Australasia having previously held the roles of Group Chief Financial Officer and Group Chief Operating Officer. Prior to joining Wellcom, Mr Lumsden was a Senior Manager within the Audit and Assurance practice of PricewaterhouseCoopers. Mr Lumsden is the Chair of the Risk Committee.
|
| Mr Leon Hoare | Non-Executive Director | Jan 2016 |
Mr Hoare has expertise across multiple Life Sciences sectors. He is currently the Managing Director of Lohmann & Rauscher, Australia & New Zealand (ANZ), a private EU based medical device company. Previously he was Managing Director of Smith & Nephew (S&N) ANZ. He served as President of S&N's Asia-Pacific Advanced Wound Management (AWM) businesses for 5 years and was a member of the Global Executive Management for the AWM Division.
|
| Ms Christine Emmanuel-Donnelly | Non-Executive Director | May 2020 |
Ms Emmanuel-Donnelly is an IP and business development professional with more than 30 years of local and international experience. She has been on the Board of the Institute of Patent and Trademark Attorneys of Australia for over a decade. Ms Emmanuel-Donnelly was Executive Manager of Business Development and Commercial at the CSIRO, was in-house IP Counsel for Unilever in the U.K., and practiced as a patent and trademark attorney for Wilson Gunn.
|
| Mr Lior Harel | Company SecretaryGeneral Counsel | May 2024 |
-
|
| Mr Swami Raote | Chief Executive Officer | Jul 2022 |
-
|
| Swami Raote | Chief Executive Officer |
-
|
|
| Jan Gielen | Chief Financial Officer |
-
|
|
| Philip Scorgie | Chief Information Officer |
-
|
|
| Joseph Amaral | Chief Medical Officer (part-time) |
-
|
|
| Ingrid Anderson | Chief People Officer |
-
|
|
| David McQuillan | Chief Technical and Scientific Officer |
-
|
|
| Lior Harel | Company SecretaryGeneral Counsel |
-
|
|
| David Morris | President Asia Pacific |
-
|
|
| Edward Graubart | President North America |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Hsbc Custody Nominees (Australia) Limited | 96,149,727 | 13.93% |
| J P Morgan Nominees Australia Pty Limited | 80,078,534 | 11.60% |
| Citicorp Nominees Pty Limited | 37,720,578 | 5.46% |
| Moggs Creek Pty Ltd (Moggs Creek Super A/C) | 19,010,112 | 2.75% |
| Lateral Innovations Pty Ltd (Trust A/C | 10,924,103 | 1.58% |
| Mr Anthony Shane Kittel Mrs Michele Therese Kittel (Kittel Family Super A/C) | 8,050,000 | 1.17% |
| Bnp Paribas Noms Pty Ltd | 7,622,413 | 1.10% |
| National Nominees Limited | 6,653,041 | 0.96% |
| Netwealth Investments Limited (Wrap Services A/C) | 5,394,880 | 0.74% |
| BNP Paribas Nominees Pty Ltd (IB AU Noms Retailclient) | 4,533,452 | 0.66% |
| BNP Paribas Nominees Pty Ltd (Agency Lending A/C) | 4,414,903 | 0.64% |
| Commonwealth Scientific And Industrial Research Organisation | 4,081,250 | 0.59% |
| Mrs Li-Hsien Tsai | 3,955,424 | 0.57% |
| Mr David Kenley | 3,755,000 | 0.54% |
| Mr Paul Gerard Brennan | 3,569,796 | 0.52% |
| Mr Matthew James Avery | 3,439,332 | 0.50% |
| Mr David Kenley i | 3,139,855 | 0.45% |
| Dr Marcus James Dermot Wagstaff Mrs Lara Kate Wagstaff | 3,072,166 | 0.45% |
| Mr Evan Philip Clucas Ms Leanne Jane Weston (Kuranga Nursery Super A/C) | 2,931,149 | 0.42% |
| Mr Chris Dawborn (Haskali Super Fund A/C) | 2,870,271 | 0.42% |
